title: Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.
abstract: OBJECTIVE
  Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa.
  
  
  METHODS
  We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR).
  
  
  RESULTS
  At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity.
  
  
  CONCLUSIONS
  Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse.
authors.affiliation: Department of Radiation Oncology, Stanford University, Stanford, California, USA.
authors.forename: Carolina E
authors.initials: CE
authors.lastname: Fasola
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Jones
authors.forename: Derek D
authors.initials: DD
authors.lastname: Huang
authors.forename: Quynh-Thu
authors.initials: QT
authors.lastname: Le
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Donaldson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009918:Orbital Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012074:Remission Induction